785 articles
GlycanAge's Dubrovnik conference targets translating 25 years of inflammaging research into real clinical tools for doctors and patients.
New research frames menopause as a mitochondrial energy crisis, positioning NMN as a targeted NAD⁺ precursor to restore cellular vitality.
A short pre-surgery course of pembrolizumab left zero relapses in colorectal cancer patients after 33 months — reshaping treatment strategy.
MIT researchers discovered that 30% of adult brain synapses are dormant but ready to activate, reshaping how we understand lifelong learning.
The FDA unveils two proof-of-concept real-time clinical trials with AstraZeneca and Amgen, aiming to slash drug development timelines.
A VEGF inhibitor implant preserved vision in 74% of wet AMD patients at 36 weeks, beating standard aflibercept therapy in a phase III trial.
Adding an IL-6 blocker to standard anti-VEGF therapy improved visual acuity by 36% more than anti-VEGF alone in a randomized DME trial.
Daraxonrasib targets RAS mutations in pancreatic cancer, showing 35% response rates and 13-month survival — far outpacing current chemo options.
Scientists discovered hundreds of unknown mini-proteins in failing hearts, potentially reshaping how we understand disease at the cellular level.
UC San Diego scientists developed an injectable hydrogel that travels the bloodstream to reduce inflammation and regenerate damaged heart tissue.
A virus infecting over 94% of US dairy herds may be found in human breast tumors, raising urgent questions about dairy and meat safety.
New imaging data shows one 25mg psilocybin dose alters brain anatomy, while sleep and APOE4 findings add to neurological health picture.
